RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kaken Pharmaceutical Co Stock

Kaken Pharmaceutical Co Revenue 2025

Kaken Pharmaceutical Co Revenue

94.04 B JPY

Ticker

4521.T

ISIN

JP3207000005

In 2025, Kaken Pharmaceutical Co's sales reached 94.04 B JPY, a 30.52% difference from the 72.04 B JPY sales recorded in the previous year.

The Kaken Pharmaceutical Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2027e71.8181,51
2026e74.8978,16
202594.0462,25
202472.0453,49
202372.9854,20
202276.0354,68
202174.9854,56
202089.2356,57
201994.1757,13
201898.4356,92
2017101.4856,11
2016109.7356,64
201593.8952,33
201488.9549,22
201387.0548,35
20128848,94
201186.4349,01
201085.0248,11
200982.9347,98
200879.9347,28
200776.4248,67
200675.5449,04

Kaken Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kaken Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kaken Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kaken Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kaken Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kaken Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kaken Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kaken Pharmaceutical Co’s growth potential.

Kaken Pharmaceutical Co Revenue, EBIT and net profit per share

DateKaken Pharmaceutical Co RevenueKaken Pharmaceutical Co EBITKaken Pharmaceutical Co Net Income
2027e71.81 B undefined0 undefined3.5 B undefined
2026e74.89 B undefined0 undefined4.93 B undefined
202594.04 B undefined21.03 B undefined13.95 B undefined
202472.04 B undefined9.51 B undefined8.03 B undefined
202372.98 B undefined8 B undefined5.44 B undefined
202276.03 B undefined17.06 B undefined9.55 B undefined
202174.98 B undefined17.79 B undefined13.41 B undefined
202089.23 B undefined26.51 B undefined19.37 B undefined
201994.17 B undefined24.59 B undefined17.78 B undefined
201898.43 B undefined27.5 B undefined19.04 B undefined
2017101.48 B undefined30.71 B undefined22.02 B undefined
2016109.73 B undefined35.15 B undefined21.14 B undefined
201593.89 B undefined20.63 B undefined12.12 B undefined
201488.95 B undefined15.87 B undefined9.74 B undefined
201387.05 B undefined14.61 B undefined8.99 B undefined
201288 B undefined15.19 B undefined8.28 B undefined
201186.43 B undefined14.19 B undefined8.21 B undefined
201085.02 B undefined11.79 B undefined6.73 B undefined
200982.93 B undefined10.64 B undefined5.58 B undefined
200879.93 B undefined8.95 B undefined5.11 B undefined
200776.42 B undefined8.12 B undefined4.6 B undefined
200675.54 B undefined8.37 B undefined3.84 B undefined

Kaken Pharmaceutical Co stock margins

The Kaken Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kaken Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kaken Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kaken Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kaken Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kaken Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kaken Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kaken Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kaken Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kaken Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kaken Pharmaceutical Co Margin History

Kaken Pharmaceutical Co Gross marginKaken Pharmaceutical Co Profit marginKaken Pharmaceutical Co EBIT marginKaken Pharmaceutical Co Profit margin
2027e62.25 %0 %4.87 %
2026e62.25 %0 %6.58 %
202562.25 %22.37 %14.83 %
202453.49 %13.2 %11.14 %
202354.2 %10.96 %7.45 %
202254.68 %22.44 %12.56 %
202154.56 %23.72 %17.88 %
202056.57 %29.71 %21.71 %
201957.13 %26.12 %18.88 %
201856.92 %27.93 %19.35 %
201756.11 %30.26 %21.7 %
201656.64 %32.03 %19.27 %
201552.33 %21.97 %12.91 %
201449.22 %17.84 %10.94 %
201348.35 %16.78 %10.33 %
201248.94 %17.26 %9.41 %
201149.01 %16.41 %9.5 %
201048.11 %13.87 %7.92 %
200947.98 %12.83 %6.73 %
200847.28 %11.2 %6.39 %
200748.67 %10.63 %6.02 %
200649.04 %11.08 %5.09 %

Kaken Pharmaceutical Co Aktienanalyse

What does Kaken Pharmaceutical Co do?

Kaken Pharmaceutical Co Ltd is a Japanese pharmaceutical company based in Tokyo. The company was founded in 1949 and has since grown continuously to establish itself as a flagship of the Japanese pharmaceutical industry. The company specializes in the production and sale of prescription and over-the-counter drugs. However, it has also heavily focused on research and development of new medications to expand its market share. Kaken Pharmaceutical's business model is to develop and manufacture high-quality products to ensure they meet the needs and requirements of customers. This includes a wide range of medications, ranging from pain relievers and antiallergics to cosmetic products. The company categorizes its products into five different categories: dermatology, pediatrics, oncology, gastroenterology, and orthopedics. Each of these categories specializes in treating and preventing various diseases, conditions, and complaints, offering a wide range of products. Dermatology is one of the key divisions of Kaken Pharmaceutical. The company offers medications for treating skin conditions such as psoriasis, eczema, dermatitis, and acne. One of its most well-known products is the anti-acne medication Isotretinoin. It works by reducing sebum production, thus reducing inflammation and pore blockage. Kaken Pharmaceutical's pediatrics products focus on treating children. Syrups and drops for symptom relief of colds, coughs, fevers, and diarrhea are among the products offered. In this category, Kaken Pharmaceutical also provides medications for treating children with ADHD. Oncology medications are offered by Kaken Pharmaceutical under the name "Kaken Pharma." These products are intended for the treatment of cancer diseases such as lung, breast, and stomach cancer. The company is constantly striving to improve its research and development to make cancer treatment more effective and efficient. The gastroenterology category focuses on treating digestive disorders such as heartburn, reflux, and gastric ulcers. Kaken Pharmaceutical has introduced several products, including drugs that inhibit stomach acid, which are offered in the form of tablets and granules. Orthopedic medications from Kaken Pharmaceutical are used to treat pain and inflammation of the skeletal system, such as relieving joint pain, arthritis, and osteoporosis. The most well-known product is the pain reliever Ibuprofen, which is available for both oral and topical use. In conclusion, Kaken Pharmaceutical Co Ltd is a company committed to meeting the medical and cosmetic needs of customers. Each product is carefully developed and manufactured to ensure the highest quality and effectiveness. With its wide range of products and research efforts, the company is an important player in the global pharmaceutical market. Kaken Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Kaken Pharmaceutical Co's Sales Figures

The sales figures of Kaken Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Kaken Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Kaken Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Kaken Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Kaken Pharmaceutical Co stock

How much revenue did Kaken Pharmaceutical Co generate this year?

Kaken Pharmaceutical Co has achieved a revenue of 94.04 B JPY this year.

How much was the turnover of the company Kaken Pharmaceutical Co compared to the previous year?

The revenue of Kaken Pharmaceutical Co has increased by 30.52% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Kaken Pharmaceutical Co?

The revenue of Kaken Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Kaken Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Kaken Pharmaceutical Co so important for investors?

The revenue of Kaken Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Kaken Pharmaceutical Co pay?

Over the past 12 months, Kaken Pharmaceutical Co paid a dividend of 75 JPY . This corresponds to a dividend yield of about 1.99 %. For the coming 12 months, Kaken Pharmaceutical Co is expected to pay a dividend of 77.7 JPY.

What is the dividend yield of Kaken Pharmaceutical Co?

The current dividend yield of Kaken Pharmaceutical Co is 1.99 %.

When does Kaken Pharmaceutical Co pay dividends?

Kaken Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Kaken Pharmaceutical Co?

Kaken Pharmaceutical Co paid dividends every year for the past 22 years.

What is the dividend of Kaken Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 77.7 JPY are expected. This corresponds to a dividend yield of 2.06 %.

In which sector is Kaken Pharmaceutical Co located?

Kaken Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kaken Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kaken Pharmaceutical Co from 6/1/2025 amounting to 75 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.

When did Kaken Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 6/1/2025.

What was the dividend of Kaken Pharmaceutical Co in the year 2024?

In the year 2024, Kaken Pharmaceutical Co distributed 150 JPY as dividends.

In which currency does Kaken Pharmaceutical Co pay out the dividend?

The dividends of Kaken Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kaken Pharmaceutical Co

Our stock analysis for Kaken Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kaken Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.